Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Fladrafinil (CRL-40,941) is a non-peptide synthetic eugeroic and the bis(4-fluorophenyl)-substituted analog of adrafinil, retaining adrafinil's N-hydroxyacetamide group. Never approved or marketed as a pharmaceutical in any jurisdiction, it is sold exclusively as an unregulated research chemical. Added to WADA's S6 (Stimulants, non-specified) category on the 2026 Prohibited List, effective 1 January 2026.
Verified purity per dollar — the cheapest that's actually been tested
No prices found for Fladrafinil.
Single-vial list prices by default for a fair head-to-head — switch to Multi-vial / bulk for pack pricing. Estimates only; verify at vendor before purchase. For research use only. Not medical advice.
Kimera Chems has the lowest single-vial Fladrafinil price at $0.011/mg among 3 COA-verified vendors on Disclosed Labs. Bulk or multi-vial deals may be lower.
What is the price range for Fladrafinil?
Research-grade Fladrafinil is listed at $0.011/mg from 1 verified source on Disclosed Labs.
How are Fladrafinil prices verified on Disclosed Labs?
Every listed vendor holds a Grade C or better trust score, computed independently from lab Certificates of Analysis — not from payments or sponsorships. Prices are scraped and fact-checked daily. Vendors cannot pay to improve their ranking.
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Use the Full safety panel filter to require endotoxin, sterility, and heavy-metals testing on the current batch — not just HPLC purity.
No clinical trials for any therapeutic indication exist; no FDA approval has been granted. The only identified human data are: (1) a 2026 peer-reviewed pharmacokinetics/metabolism study for anti-doping purposes (Krug et al., Drug Testing and Analysis), which administered fladrafinil orally to healthy volunteers and confirmed metabolism to flmodafinil, flmodafinil acid, and flmodafinil sulfone; and (2) unverified patent-holder claims from 1984 describing oral 50 mg capsules for hypersomnia/psychasthenia with reported 'excellent results' over 2–8 weeks—this is not an independently published or peer-reviewed trial. Animal studies (mice/rats, intraperitoneal, 16–256 mg/kg) from the 1984 Lafon patent reported reduced barbiturate-induced sleep duration, increased spontaneous motor activity, reduced inter-group aggression, improved motor recovery following hypoxic stress, and prolonged amphetamine-induced stereotypy.
This platform provides informational tools only, not medical advice.
Prices verified as of July 2026. Actual prices may vary. For research use only.
Disclosed Labs